For the quarter ending 2025-09-30, HBIO had -$625K decrease in cash & cash equivalents over the period. $877K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,231 | -52,622 |
| Depreciation | 425 | 862 |
| Amortization of intangible assets | 899 | 2,409 |
| Goodwill impairment - note 4 | 0 | 47,951 |
| Amortization of deferred financing costs | 357 | 341 |
| Stock-based compensation | 324 | 1,072 |
| Deferred income taxes and other | -20 | 573 |
| Loss on equity securities - note 6 | 0 | 0 |
| Loss on pension settlement - note 8 | 0 | - |
| Accounts receivable | 210 | -3,232 |
| Inventories | -637 | -1,647 |
| Other assets | -368 | -53 |
| Accounts payable and other liabilities | -271 | 1,774 |
| Contract liabilities | -234 | -405 |
| Net cash provided by operating activities | 1,084 | 5,741 |
| Additions to property, plant and equipment | 207 | 602 |
| Capitalized software development costs | 141 | 314 |
| Proceeds from sale of marketable equity securities | 0 | 0 |
| Net cash used in investing activities | -348 | -916 |
| Borrowing from revolving line of credit | 0 | 0 |
| Repayment of revolving line of credit | 0 | 0 |
| Repayment of term debt | 1,000 | 2,000 |
| Payment of debt issuance costs | 254 | 433 |
| Proceeds from exercise of stock options and employee stock purchase plan | 0 | 46 |
| Taxes paid related to net share settlement of equity awards | 24 | 75 |
| Net cash (used in) provided by financing activities | -1,278 | -2,462 |
| Effect of exchange rate changes on cash | -83 | 971 |
| Increase in cash and cash equivalents | -625 | 3,334 |
| Cash and cash equivalents at beginning of period | 4,108 | - |
| Cash and cash equivalents at end of period | 6,817 | - |
HARVARD BIOSCIENCE INC (HBIO)
HARVARD BIOSCIENCE INC (HBIO)